Additionally, Ongoing research is exploring the use of PCSK9 inhibitors in various patient populations, including those with diabetes (9, 10), chronic kidney disease (11), and refractory dyslipidemia (12). This evidence concerns the gene PCSK9 and metabolic syndrome.